DOCSLIB.ORG

Preventive Medications List Effective: July 1, 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Preventive Medications List Effective: July 1, 2013 In addition to a healthy lifestyle, preventive medications can help people avoid many illnesses and conditions. A consumer-directed health (CDH) plan that includes preventive medications can help support the goal of ongoing good health. This list provides examples of your plan’s preventive medications. The medications are categorized based on the medical conditions that they are used to prevent. Coverage prior to the deductible being met may not be provided for every dosage form of a listed medication. Please call Member Services at 877.223.4721. This list is periodically reviewed and updated to ensure that the drugs listed meet the criteria for inclusion. This list includes medications sometimes used for prevention and sometimes for treatment. PDL8745C Preventive Medications List ANEMIA IN CHILDREN CANCER TREATMENT, SIDE FERROUS SULFATE LIQUID DROPS FOR EFFECTS FROM INFANTS (SUCH AS FER-IN-SOL) ARANESP ASTHMA DARBEPOETIN ALFA EPOGEN, PROCRIT SINGULAIR EPOETIN ALFA MONTELUKAST NEUPOGEN ACCOLATE FILGRASTIM ZAFIRLUKAST DEPO-PROVERA ZYFLO CR MEDROXYPROGESTERONE ZILEUTON MESNEX BONE DISEASE AND FRACTURES MESNA NEULASTA FOSAMAX, FOSAMAX PLUS D PEGFILGRASTIM ALENDRONATE LEUKINE FORTICAL, MIACALCIN SARGRAMOSTIM CALCITONIN XGEVA CAVITIES DENOSUMAB PEDIATRIC FLUORIDE VITAMIN BONIVA DROPS IBANDRONATE PREVIDENT EVISTA RALOXIFENE SODIUM FLUORIDE ACTONEL COLONOSCOPY PREPARATION RISEDRONATE RECLAST COLYTE, GOLYTELY, HALFLYTELY, ZOLEDRONIC ACID NULYTELY, TRILYTE, MOVIPREP POLYETHYLENE GLYCOL BREAST CANCER RECURRENCE VISICOL, OSMOPREP, SUPREP TAMOXIFEN SODIUM PHOSPHATE SALTS ARIMIDEX DIABETES, COMPLICATIONS OF ANASTROZOLE AROMASIN INSULINS: EXEMESTANE NOVOLOG, NOVOLOG 70/30 FEMARA ASPART, ASPART PROTAMINE MIX LETROZOLE LEVEMIR DETEMIR LANTUS, LANTUS SOLOSTAR GLARGINE Preventive Medications List APIDRA, APIDRA SOLOSTAR ESTROGEN REPLACEMENT AND GLULISINE OTHER HORMONES HUMULIN, NOVOLIN PREMARIN INSULIN HUMALOG, 50/50, 75/25 CONJUGATED ESTROGEN TABLETS PREMPRO, PREMPHASE LISPRO, LISPRO PROTAMINE MIX CONJUGATED ESTROGEN/ NON-INSULIN MEDICINES: MEDROXYPROGESTERONE BYETTA ESTRACE ESTRADIOL TABLETS EXENATIDE AMARYL CLIMARA ESTRADIOL TRANSDERMAL GLIMEPIRIDE GLUCOTROL, METAGLIP ESTRADERM ESTRADIOL TRANSDERMAL GLIPIZIDE AND COMBINATIONS DIABETA, GLYNASE, GLUCOVANCE VIVELLE DOT ESTRADIOL TRANSDERMAL GLYBURIDE AND COMBINATIONS TRADJENTA DIVIGEL ESTRADIOL, GEL LINAGLIPTIN VICTOZA EVAMIST ESTRADIOL, TRANSDERMAL SPRAY LIRAGLUTIDE FORTAMET, GLUCOPHAGE, COMBIPATCH GLUMETZA, RIOMET ESTRADIOL/NORETHINDRONE, TRANSDERMAL METFORMIN MAKENA STARLIX HYDROXYPROGESTERONE CAPROATE NATEGLINIDE PROVERA ACTOS, DUETACT, ACTOPLUS MET MEDROXYPROGESTERONE PIOGLITAZONE AND COMBINATIONS CRINONE, PROMETRIUM SYMLIN PROGESTERONE PRAMLINTIDE CENESTIN PRANDIN SYNTHETIC CONJUGATED ESTROGENS, A REPAGLINIDE ENJUVIA AVANDIA, AVANDAMET, SYNTHETIC CONJUGATED ESTROGENS, B AVANDARYL ROSIGLITAZONE AND COMBINATIONS GOUT ONGLYZA, KOMBIGLYZE XR ZYLOPRIM SAXAGLIPTIN AND COMBINATIONS ALLOPURINOL JANUVIA, JANUMET COLCRYS SITAGLIPTIN AND COMBINATIONS COLCHICINE Preventive Medications List GUM DISEASE ZOCOR ARESTIN SIMVASTATIN MINOCYCLINE OTHER AGENTS: HEART DISEASE AND STROKE PREVALITE, QUESTRAN BLOOD THINNER MEDICINES: CHOLESTYRAMINE WELCHOL ASPIRIN, 81 MG OR 325 MG COLESEVELAM HEPARIN COLESTID AGGRENOX COLESTIPOL ASA/DIPYRIDAMOLE ZETIA PLAVIX EZETIMIBE CLOPIDOGREL VYTORIN FRAGMIN EZETIMIBE/SIMVASTATIN DALTEPARIN FENOGLIDE, LIPOFEN, TRICOR, LOVENOX ANTARA, TRIGLIDE ENOXAPARIN FENOFIBRATE ARIXTRA TRILIPIX FONDAPARINUX FENOFIBRIC ACID EFFIENT LOPID PRASUGREL GEMFIBROZIL XARELTO NIACOR, NIASPAN ER RIVAROXABAN NIACIN ` BRILINTA ADVICOR TICAGRELOR NIACIN/LOVASTATIN COUMADIN, JANTOVEN SIMCOR WARFARIN NIACIN ER/SIMVASTATIN CHOLESTEROL LOWERING LOVAZA MEDICINES OMEGA-3-ACID ETHYL ESTERS HIGH BLOOD PRESSURE HMG-COA REDUCTASE MEDICINES INHIBITORS: ACE INHIBITORS AND LIPITOR COMBINATIONS: ATORVASTATIN MEVACOR, ALTOPREV LOTENSIN, LOTENSIN HCT LOVASTATIN BENAZEPRIL PRAVACHOL VASOTEC, VASERETIC PRAVASTATIN ENALAPRIL CRESTOR MONOPRIL, MONOPRIL HCT ROSUVASTATIN FOSINOPRIL Preventive Medications List PRINIVIL, PRINZIDE, ZESTRIL, CALCIUM CHANNEL BLOCKERS: ZESTORETIC NORVASC LISINOPRIL ACCUPRIL, ACCURETIC AMLODIPINE CARDIZEM, CARDIZEM LA, QUINAPRIL CARTIA XT, TIAZAC ER ACE RECEPTOR BLOCKERS AND DILTIAZEM COMBINATIONS: ADALAT CC, PROCARDIA EDARBI NIFEDIPINE SULAR AZILSARTAN ATACAND, ATACAND HCT NISOLDIPINE CALAN, COVERA HS, ISOPTIN SR, CANDESARTAN TEVETEN, TEVETEN HCT VERELAN VERAPAMIL EPROSARTAN AVAPRO, AVALIDE DIURETICS AND COMBINATIONS: IRBESARTAN COZAAR, HYZAAR HYDROCHLOROTHIAZIDE INDAPAMIDE LOSARTAN BENICAR, BENICAR HCT MIDAMOR AMILORIDE OLMESARTAN MICARDIS, MICARDIS HCT ZAROXOLYN METOLAZONE TELMISARTAN DIOVAN, DIOVAN HCT ALDACTONE SPIRONOLACTONE VALSARTAN DYAZIDE, MAXZIDE BETA BLOCKERS AND TRIAMTERENE-HCTZ COMBINATIONS: HIGH BLOOD PRESSURE TENORMIN, TENORETIC MEDICINES, MISCELLANEOUS: ATENOLOL HYDRALAZINE ZEBETA, ZIAC TEKTURNA, TEKTURNA HCT, BISOPROLOL LOPRESSOR, TOPROL XL TEKAMLO, AMTURNIDE, METOPROLOL VALTURNA BYSTOLIC ALISKIREN AND COMBINATIONS NEBIVOLOL LOTREL INDERAL LA, INNOPRAN XL AMLODIPINE/BENAZEPRIL PROPRANOLOL AZOR AMLODIPINE/OLMESARTAN TRIBENZOR AMLODIPINE/OLMESARTAN/ HYDROCHLOROTHIAZIDE Preventive Medications List TWYNSTA VIRUS AMLODIPINE/TELMISARTAN AMANTADINE EXFORGE ZOVIRAX AMLODIPINE/VALSARTAN ACYCLOVIR EXFORGE HCT FAMVIR AMLODIPINE/VALSARTAN/ FAMCICLOVIR HYDROCHLOROTHIAZIDE FOSCAVIR COREG, COREG CR FOSCARNET CARVEDILOL CATAPRES, CLORPRES CYTOVENE GANCICLOVIR CLONIDINE CARDURA TAMIFLU OSELTAMIVIR DOXAZOSIN HYTRIN VALTREX VALACYCLOVIR TERAZOSIN VALCYTE INFECTION VALGANCICLOVIR RELENZA FUNGAL ZANAMIVIR MEPRON KIDNEY DISEASE, HIGH ATOVAQUONE NEBUPENT, PENTAM PHOSPHATE LEVELS PENTAMIDINE PHOSLO, PHOSLYRA NOXAFIL CALCIUM ACETATE POSACONAZOLE FOSRENOL LANTHANUM MALARIA RENVELA, RENAGEL PRIMAQUINE SEVELAMER COARTEM ARTEMETHER/LUMEFANTRINE NAUSEA AND DIZZINESS MALARONE PROCHLORPERAZINE ATOVAQUONE/PROGUANIL PROMETHAZINE PLAQUENIL EMEND HYDROXYCHLOROQUINE APREPITANT DARAPRIM ANZEMET PYRIMETHAMINE DOLASETRON MARINOL DRONABINOL SANCUSO GRANISETRON Preventive Medications List ANTIVERT MISCELLANEOUS AGENTS: MECLIZINE ZOFRAN, ZOFRAN ODT PYLERA BISMUTH/METRONIDAZOLE/ ONDANSETRON TETRACYCLINE TRANSDERM-SCOP, SCOPACE CARAFATE SCOPOLAMINE SUCRALFATE OBESITY* PROTON PUMP INHIBITORS: DIETHYLPROPION XENICAL NEXIUM ORLISTAT ESOMEPRAZOLE BONTRIL PREVACID PHENDIMETRAZINE LANSOPRAZOLE ADIPEX-P, IONAMIN PROTONIX PHENTERMINE PANTOPRAZOLE ACIPHEX PREGNANCY RABEPRAZOLE BIRTH CONTROL MEDICINES VITAMINS OR MINERALS, LOW TAKEN BY MOUTH BIRTH CONTROL DEVICES: LEVELS OF DIAPHRAGMS, SKIN PATCH SYSTEMS, PRESCRIPTION PRENATAL VITAMINS INJECTABLE BIRTH CONTROL VITAMINS: B12, K SMOKING-CESSATION THERAPY ZYBAN BUPROPION NICOTROL NICOTINE PRODUCTS CHANTIX VARENICLINE ULCER DISEASE H2-ANTAGONISTS: CIMETIDINE PEPCID FAMOTIDINE AXID NIZATIDINE ZANTAC RANITIDINE *Prior authorization is required. Express Scripts manages your prescription benefit for your employer, plan sponsor, or health plan. Please note: Brand names are shown in italics in each category. All rights in the product names of all third-party products appearing here, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. PDL8745C List 1+2 10.12 *0000000PDL8745C* *0000000PDL8745C*.
Recommended publications
  • Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer Among Women 55 to 74 Years of Age

    Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer Among Women 55 to 74 Years of Age

    Published OnlineFirst July 5, 2013; DOI: 10.1158/1055-9965.EPI-13-0414 Cancer Epidemiology, Research Article Biomarkers & Prevention Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age Jean A. McDougall1, Kathleen E. Malone1, Janet R. Daling1, Kara L. Cushing-Haugen1, Peggy L. Porter1,2, and Christopher I. Li1 Abstract Background: Mechanistic studies largely support the chemopreventive potential of statins. However, results of epidemiologic studies investigating statin use and breast cancer risk have been inconsistent and lacked the ability to evaluate long-term statin use. Methods: We used data from a population-based case–control study of breast cancer conducted in the Seattle–Puget Sound region to investigate the relationship between long-term statin use and breast cancer risk. Nine hundred sixteen invasive ductal carcinoma (IDC) and 1,068 invasive lobular carcinoma (ILC) cases in patients 55 to 74 years of age diagnosed between 2000 and 2008 were compared with 902 control women. All participants were interviewed in-person and data on hypercholesterolemia and all episodes of lipid-lowering medication use were collected through a structured questionnaire. We assessed the relationship between statin use and IDC and ILC risk using polytomous logistic regression. Results: Current users of statins for 10 years or longer had a 1.83-fold increased risk of IDC [95% confidence interval (CI): 1.14–2.93] and a 1.97-fold increased risk of ILC (95% CI: 1.25–3.12) compared with never users of statins. Among women diagnosed with hypercholesterolemia, current users of statins for 10 years or longer had more than double the risk of both IDC (OR: 2.04, 95% CI: 1.17–3.57) and ILC (OR: 2.43, 95% CI: 1.40–4.21) compared with never users.
  • Pharmacokinetic Interactions Between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance

    Pharmacokinetic Interactions Between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance

    life Review Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance Laura Rombolà 1 , Damiana Scuteri 1,2 , Straface Marilisa 1, Chizuko Watanabe 3, Luigi Antonio Morrone 1, Giacinto Bagetta 1,2,* and Maria Tiziana Corasaniti 4 1 Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, Section of Preclinical and Translational Pharmacology, University of Calabria, 87036 Rende, Italy; [email protected] (L.R.); [email protected] (D.S.); [email protected] (S.M.); [email protected] (L.A.M.) 2 Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy 3 Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 981-8558 Sendai, Japan; [email protected] 4 School of Hospital Pharmacy, University “Magna Graecia” of Catanzaro and Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0984-493462 Received: 28 May 2020; Accepted: 30 June 2020; Published: 4 July 2020 Abstract: The therapeutic efficacy of a drug or its unexpected unwanted side effects may depend on the concurrent use of a medicinal plant. In particular, constituents in the medicinal plant extracts may influence drug bioavailability, metabolism and half-life, leading to drug toxicity or failure to obtain a therapeutic response. This narrative review focuses on clinical studies improving knowledge on the ability of selected herbal medicines to influence the pharmacokinetics of co-administered drugs. Moreover, in vitro studies are useful to anticipate potential herbal medicine-drug interactions.
  • Fasted and Fed State Human Duodenal Fluids: Characterization, Drug Solubility, and Comparison to Simulated Fluids and with Human Bioavailability

    Fasted and Fed State Human Duodenal Fluids: Characterization, Drug Solubility, and Comparison to Simulated Fluids and with Human Bioavailability

    European Journal of Pharmaceutics and Biopharmaceutics 163 (2021) 240–251 Contents lists available at ScienceDirect European Journal of Pharmaceutics and Biopharmaceutics journal homepage: www.elsevier.com/locate/ejpb Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability D. Dahlgren a, M. Venczel b,c, J.-P. Ridoux b,c, C. Skjold¨ a, A. Müllertz d, R. Holm e, P. Augustijns f, P.M. Hellstrom¨ g, H. Lennernas¨ a,* a Department of Pharmaceutical Biosciences, Biopharmaceutics, Uppsala University, Sweden b Global CMC Development Sanofi, Frankfurt, Germany c Global CMC Development Sanofi, Vitry, France d Physiological Pharmaceutics, University of Copenhagen, Copenhagen, Denmark e Drug Product Development, Janssen R&D, Johnson & Johnson, Beerse, Belgium f Drug Delivery and Disposition, KU Leuven, Leuven, Belgium g Department of Medical Sciences, Gastroenterology/Hepatology, Uppsala University, Sweden ARTICLE INFO ABSTRACT Keywords: Accurate in vivo predictions of intestinal absorption of low solubility drugs require knowing their solubility in Bioavailability physiologically relevant dissolution media. Aspirated human intestinal fluids (HIF) are the gold standard, fol­ Food effects lowed by simulated intestinal HIF in the fasted and fed state (FaSSIF/FeSSIF). However, current HIF charac­ Drug solubility terization data vary, and there is also some controversy regarding the accuracy of FaSSIF and FeSSIF for Human intestinal fluids predicting drug solubility in HIF. This study aimed at characterizing fasted and fed state duodenal HIF from 16 Drug absorption Drug dissolution human volunteers with respect to pH, buffer capacity, osmolarity, surface tension, as well as protein, phos­ Drug delivery pholipid, and bile salt content.
  • Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies

    Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies

    Chinese Journal of Physiology 61(1): 1-13, 2018 1 DOI: 10.4077/CJP.2018.BAG516 Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies Tzu-Tung Chang, Chia-Jung Yang, Yu-Chi Lee, and Sheng-Nan Wu Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan, Republic of China Abstract Telmisartan (Tel) is recognized as a non-peptide blocker of AT1R. Whether this agent has any direct effects on ion currents remains unexplored. In whole-cell current recordings, addition of Tel + increased the peak amplitude of voltage-gated Na (NaV) current (INa) accompanied by the increased time constant of INa inactivation in differentiated NSC-34 motor neuron-like cells. Tel-stimulated INa in these cells is unlinked to either blockade of AT1R or activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). In order to explore how this compound affects the amplitude and kinetics of INa in neurons, a Hodgkin-Huxley-based (HH-based) model designed to mimic effect of Tel on the functional activities of neurons was computationally created in this study. In this framework, the parameter for h inactivation gating variable, which was changed in a stepwise fashion, was implemented + + to predict changes in membrane potentials (V) as a function of maximal Na (GNa), K conductance (GK), or both. As inactivation time course of INa was increased, the bifurcation point of V versus GNa became lower, and the range between subcritical and supercritical values at the bifurcation of V versus GK correspondingly became larger.
  • The Differential Effects of Statins on the Metastatic Behaviour of Prostate Cancer

    The Differential Effects of Statins on the Metastatic Behaviour of Prostate Cancer

    British Journal of Cancer (2012) 106, 1689–1696 & 2012 Cancer Research UK All rights reserved 0007 – 0920/12 www.bjcancer.com The differential effects of statins on the metastatic behaviour of prostate cancer *,1 1 1 2,3 2,3 2,4 1,2,4 M Brown , C Hart , T Tawadros , V Ramani , V Sangar , M Lau and N Clarke 1 Genito Urinary Cancer Research Group, University of Manchester, Paterson Institute for Cancer Research, Manchester Academic Health Science Centre, 2 The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK; Department of Urology, The Christie NHS Foundation 3 Trust, Wilmslow Road, Manchester M20 4BX, UK; Department of Urology, University Hospital of South Manchester NHS Trust, Manchester M23 9LT, 4 UK; Department of Urology, Salford Royal NHS Foundation Trust, Stott Lane, Manchester M6 8HD, UK BACKGROUND: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown. METHODS: Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non- malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins. RESULTS: Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1 mM) and rosuvastatin (5 mM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93–77.04%; Po0.05) and significantly reducing both 2 2 number (76.2±8.29 vs 122.9±2.48; P ¼ 0.0055) and size (0.2±0.0058 mm vs 0.27±0.012 mm ; P ¼ 0.0019) of colonies formed within BMS.
  • What Precautions Should We Use with Statins for Women of Childbearing

    What Precautions Should We Use with Statins for Women of Childbearing

    CLINICAL INQUIRIES What precautions should we use with statins for women of childbearing age? Chaitany Patel, MD, Lisa Edgerton, PharmD New Hanover Regional Medical Center, Wilmington, North Carolina Donna Flake, MSLS, MSAS Coastal Area Health Education Center, Wilmington, NC EVIDENCE- BASED ANSWER Statins are contraindicated for women who are on its low tissue-penetration properties. pregnant or breastfeeding. Data evaluating statin Cholesterol-lowering with simvastatin 40 mg/d did use for women of childbearing age is limited; how- not disrupt menstrual cycles or effect luteal phase ever, they may be used cautiously with adequate duration (strength of recommendation: C). contraception. Pravastatin may be preferred based CLINICAL COMMENTARY Use statins only as a last resort Before reading this review, I had not been for women of childbearing age ® Dowdenaware Health of the serious Media effects of statin medications I try to follow the USPSTF recommendations and on the developing fetus. In conversations with not screen women aged <45 years without coro- my colleagues, I found that the adverse effects nary artery disease riskCopyright factors for Fhyperlipidemia.or personalof usestatins onlyduring pregnancy are not readily When a woman of any age needs treatment, my known. Such information needs to be more first-line therapy is lifestyle modification. Given the widely disseminated. risks of statin drugs to the developing fetus, Ariel Smits, MD women with childbearing potential should give Department of Family Medicine, Oregon Health & Science fully informed consent and be offered reliable University, Portland contraception before stating statin therapy. I Evidence summary anal, cardiac, tracheal, esophageal, renal, Hydroxymethyl glutaryl coenzyme A and limb deficiency (VACTERL associa- (HMG CoA) reductase inhibitors, com- tion), intrauterine growth retardation monly called statins, have been on the (IUGR), and demise in fetuses exposed market since the late 1980s.
  • Pharmacokinetic Interactions of Pioglitazone

    Pharmacokinetic Interactions of Pioglitazone

    Department of Clinical Pharmacology University of Helsinki Finland PHARMACOKINETIC INTERACTIONS OF PIOGLITAZONE Tiina Jaakkola ACADEMIC DISSERTATION To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in Auditorium 2 of Biomedicum, on August 24th, 2007, at 12 noon. Helsinki 2007 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 1 117.7.20077.7.2007 221:11:231:11:23 Supervisors: Professor Pertti Neuvonen, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Docent Janne Backman, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Reviewers: Docent Kimmo Malminiemi, MD, MSc Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland Professor emeritus Pertti Pentikäinen, MD Department of Medicine University of Helsinki Helsinki, Finland Opponent: Professor Kari Kivistö, MD Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland ISBN 978-952-92-2224-7 (paperback) ISBN 978-952-10-4020-7 (PDF, http://ethesis.helsinki.fi ) Helsinki 2007 Yliopistopaino JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 2 117.7.20077.7.2007 221:11:551:11:55 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 3 117.7.20077.7.2007 221:11:551:11:55 CONTENTS CONTENTS ABBREVIATIONS.......................................................................................................................................... 6 LIST OF ORIGINAL PUBLICATIONS.......................................................................................................
  • Pharmacokinetic Interactions of Drugs with St John's Wort

    Pharmacokinetic Interactions of Drugs with St John's Wort

    http://www.paper.edu.cn Pharmacokinetic interactions of Journal of Psychopharmacology 18(2) (2004) 262–276 © 2004 British Association drugs with St John’s wort for Psychopharmacology ISSN 0269-8811 SAGE Publications Ltd, London, Thousand Oaks, CA and New Delhi 10.1177/0269881104042632 Shufeng Zhou Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Eli Chan Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Shen-Quan Pan Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore. Min Huang Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510089, PR China. Edmund Jon Deoon Lee Department of Pharmacology, Faculty of Medicine, National University of Singapore, Singapore. Abstract There is a worldwide increasing use of herbs which are often cancer patients receiving irinotecan treatment. St John’s wort did not administered in combination with therapeutic drugs, raising the alter the pharmacokinetics of tolbutamide, but increased the incidence potential for herb–drug interactions. St John’s wort (Hypericum of hypoglycaemia. Several cases have been reported that St John’s wort perforatum) is one of the most commonly used herbal antidepressants. A decreased cyclosporine blood concentration leading to organ rejection. literature search was performed using Medline (via Pubmed), Biological St John’s wort caused breakthrough bleeding and unplanned pregnancies Abstracts, Cochrane Library, AMED, PsycINFO and Embase (all from their when used concomitantly with oral contraceptives. It also caused inception to September 2003) to identify known drug interaction with serotonin syndrome when coadministered with selective serotonin- St John’s wort. The available data indicate that St John’s wort is a reuptake inhibitors (e.g.
  • Prevalence of Drug Interactions in Hospitalized Elderly Patients: a Systematic Review

    Prevalence of Drug Interactions in Hospitalized Elderly Patients: a Systematic Review

    Supplementary material Eur J Hosp Pharm Prevalence of drug interactions in hospitalized elderly patients: a systematic review Luciana Mello de Oliveira 1,2; Juliana do Amaral Carneiro Diel1; Alessandra Nunes3; Tatiane da Silva Dal Pizzol 1,2,3 1Programa de Pós-Graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul. 2Programa de Pós-Graduação em Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. 3Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Corresponding author: Luciana Mello de Oliveira – [email protected] and Tatiane da Silva Dal Pizzol - [email protected] Supplementary Table 3: Number of patients with interaction, number of DDI per patient with at least one DDI, drugs or drug classes mostly involved with DDI and drug combinations mostly involved with DDI. In cases which prevalence were described, we reported the three drugs mostly involved with drug interactions or the three drug combinations (or drug classes) mostly involved with DDI. ACE: angiotensin-converting enzyme. NA: not available. NSAID: non-steroidal anti-inflammatory drugs. PPI: proton-pump inhibitors. # of patients with # of DDI per patient with First autor interactions interaction Drugs or drug classes mostly involved with DDI Drug combinations mostly involved with DDI Barak-Tsarfir O, et al (61) Unclear: around 56 patients NA NA NA Warfarin; digitoxin; prednisolone antithrombotic agents; non-steroidal anti- 70 (evaluated only serious or inflammatory agents; angiotensin converting enzyme Blix HS, et al (29) contraindicated DDI) NA inhibitors N/A Serious: chlorpromazine + promethazine; chlorpromazine + haloperidol; haloperidol + promethazine; diazepam + phenobarbital; risperidone + haloperidol; carbamazepine + ketoconazole; carbamazepine + chlorpromazine; haloperidol + ketoconazole; chlorpromazine + ketoconazole; chlorpromazine + sodium phosphate.
  • ACCOLATE® (Zafirlukast) TABLETS DESCRIPTION

    ACCOLATE® (Zafirlukast) TABLETS DESCRIPTION

    ACCOLATE® (zafirlukast) TABLETS DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o­ tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575.7 and the structural formula is: The empirical formula is: C31H33N3O6S Zafirlukast, a fine white to pale yellow amorphous powder, is practically insoluble in water. It is slightly soluble in methanol and freely soluble in tetrahydrofuran, dimethylsulfoxide, and acetone. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium, lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Patients with asthma were found in one study to be 25­ 100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and Reference ID: 3407275 inhibited inhaled LTD4-induced influx of eosinophils into animal lungs. Inhalational challenge studies in sensitized sheep showed that zafirlukast suppressed the airway responses to antigen; this included both the early- and late-phase response and the nonspecific hyperresponsiveness.
  • Effect of Testosterone on the Growth and Virulence of Staphylococcus Aureus

    Effect of Testosterone on the Growth and Virulence of Staphylococcus Aureus

    Loyola University Chicago Loyola eCommons Master's Theses Theses and Dissertations 1966 Effect of Testosterone on the Growth and Virulence of Staphylococcus aureus Joseph Lloyd Waner Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_theses Part of the Medicine and Health Sciences Commons Recommended Citation Waner, Joseph Lloyd, "Effect of Testosterone on the Growth and Virulence of Staphylococcus aureus" (1966). Master's Theses. 2065. https://ecommons.luc.edu/luc_theses/2065 This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1966 Joseph Lloyd Waner Effect of Testosterone on the Growth and Virulence of Staphlococcus aureus By Joseph L. Waner Microbiology Department Stritch School of Medicine A thesis submitted to the Faculty of the Graduate School of Loyola University in partial fulfillment of the requirements for the degree of Master of Science. TABLE OF CONTENTS Lifv--------------------------------------------- ii Abstract-------------------------------------------P. 1 Introd~ction---------------------------------------P. 2-3 ~a terials and Nethod s------------------- ---------------P. 4-10 S. aureus strains------------ -----------------------P. 4 Testosterone Bolutions------------·------·---------P.
  • British Journal of Nutrition (2013), 109, 1923–1933 Doi:10.1017/S0007114512003972 Q the Authors 2012

    British Journal of Nutrition (2013), 109, 1923–1933 Doi:10.1017/S0007114512003972 Q the Authors 2012

    Downloaded from British Journal of Nutrition (2013), 109, 1923–1933 doi:10.1017/S0007114512003972 q The Authors 2012 https://www.cambridge.org/core Dose–response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults Lynn Cialdella-Kam1, David C. Nieman1*, Wei Sha2, Mary Pat Meaney1, Amy M. Knab1 . IP address: and R. Andrew Shanely1 1Human Performance Laboratory, North Carolina Research Campus, Appalachian State University, 170.106.35.76 600 Laureate Way, Kannapolis, NC, USA 2UNC Charlotte, Bioinformatics Services Division, Kannapolis, NC, USA (Submitted 10 April 2012 – Final revision received 3 August 2012 – Accepted 12 August 2012 – First published online 14 November 2012) , on 23 Sep 2021 at 13:28:33 Abstract Quercetin, a flavonol in fruits and vegetables, has been demonstrated to have antioxidant, anti-inflammatory and immunomodulating influences. The purpose of the present study was to determine if quercetin, vitamin C and niacin supplements (Q-500 ¼ 500 mg/d of quer- cetin, 125 mg/d of vitamin C and 5 mg/d of niacin; Q-1000 ¼ 1000 mg/d of quercetin, 250 mg/d of vitamin C and 10 mg/d of niacin) would alter small-molecule metabolite profiles and serum quercetin conjugate levels in adults. Healthy adults (fifty-eight women and forty-two , subject to the Cambridge Core terms of use, available at men; aged 40–83 years) were assigned using a randomised double-blinded placebo-controlled trial to one of three supplement groups (Q-1000, Q-500 or placebo). Overnight fasted blood samples were collected at 0, 1 and 3 months.